Quince Therapeutics files Orphai acquisition financials; pipeline details disclosed

Quince Therapeutics, Inc.

Audited Orphai financials for FY2024-2025 and unaudited Q1 2026 now filed; pro forma combined financials included.
Lead asset LAM-001 (inhaled rapamycin) targets PH-ILD, BOS, and SAPH; Phase 2b PH-ILD data expected Q1 2028.
Phase 2 BOS trial fully enrolled, preliminary data expected Q1 2027; SAPH Phase 2 to start late 2026.
Acquisition funded by $115M upfront private placement; potential additional $83M from warrant exercises.
Orphai's former COO Keith Fandrick joins as Head of Technical Operations; Brigette Roberts remains Chief Corporate Affairs Officer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.